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Abstract  Renal  cancers  account  for  approximately  3%  of  adult  cancers  and  the  mean  age  of
diagnosis is  65,  with  men  affected  two  to  three  times  more  frequently  than  women.  However,
an increase  is  being  seen  in  kidney  tumours  also  in  young  adults  and  in  women.  The  classiﬁ-
cation of  renal  tumours  includes  both  benign  and  malignant  tumours,  and  is  currently  quite
exhaustive,  but  may  be  even  more  extensive  in  the  coming  years,  particularly  for  tumours  in
renal impairment.  Except  for  certain  speciﬁc  entities  (such  as  chromophobe  carcinoma),  two
criteria are  required  to  correctly  classify  malignant  kidney  tumours:  the  Fuhrman  grade,  and
the pTNM  stage,  deﬁning  tumour  extension.  The  stage  and  grade  are  applicable  in  the  same
way, regardless  of  the  nature  of  the  tumours;  for  a  given  group,  they  are  the  best  prognostic
factors.
© 2012  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
Renal  cancer  accounts  for  approximately  3%  of  adult  cancers,  occurring  at  a  mean  age  of
65,  with  male  predominance  (sex  ratio  3/1).  In  its  disseminated  form,  it  is  an  aggressive
tumour  (kidney  cancer  holds  the  sixth  position  in  the  causes  of  death  through  cancer).
The  histological  classiﬁcation  of  kidney  tumours,  updated  by  the  World  Health  Organisa-
tion  in  2004,  is  primarily  based  on  morphological  criteria  (the  appearance  of  the  cells  clear
or  eosinophilic  and  whether  the  architecture  is  papillary  or  not)  [1].  Besides  clear  cell,  pap-
illary  and  chromophobe  renal  carcinomas,  this  classiﬁcation  in  addition  distinguishes  new
entities  due  to  their  histological  appearance,  prognosis  or  genotypic  alterations  (Boxed
text  1  and  Table  1).
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Boxed  text  1  2004  WHO  classiﬁcation  of
epithelial  tumours  of  the  kidney.
Clear  cell  carcinoma.
Multilocular  cystic  renal  cell  carcinoma*.
Papillary  carcinoma  of  the  kidney.
Chromophobe  renal  cell  carcinoma.
Bellini  duct  carcinoma.
Renal  medullary  carcinoma.
Carcinoma  with  Xp11.2  translocation*.
Neuroblastoma-associated  renal  cell  carcinoma*.
Low-grade  mucinous  tubular  and  spindle  cell
carcinoma*.
Unclassiﬁable  carcinoma.
Papillary  adenoma.
Oncocytoma.
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h*Entities  new  to  the  2004  classiﬁcation.
In  practice,  histological  analysis  seeks  to  identify  the
lear  or  eosinophilic  (oxyphilic)  principal  cell  population
nd  the  predominant  acinar,  papillary  or  cystic  architecture.
mmunohistochemical  analysis  points  towards  the  origin  of
he  cell  population  responsible  for  tumour  proliferation
Table  2),  whereas  cytogenetic  analysis  sets  out  the  principal
ramework  of  the  major  groups  of  renal  tumours  (Table  1).
To  fully  appreciate  the  risk  of  progression  of  these
umours,  two  histo-prognostic  assessments  are  required.
he  Fuhrman  grade  takes  into  account  nuclear  size  and
hape  and  the  size  of  the  nucleoli.  It  deﬁnes  the  differen-
iated  or  non-differentiated  character  of  the  tumour  cells.
Table  1  Main  genetic  alterations  observed  in  renal  cell  carcin
Histological  type  
Clear  cell  carcinoma  
Xp11  translocation  carcinoma  
Carcinoma  associating  TFEB  
Papillary  carcinoma  (type  1)  
Mucinous  tubular  and  spindle  cell  carcinoma  
Chromophobe  carcinoma
Clear  cell  papillary  carcinoma  said  to  be  of  end-stage  renal  dis
Table  2  Immunohistochemical  proﬁle  of  the  main  epithelial  t
Histological  type
Clear  cell  carcinoma  
Papillary  carcinoma  
Mucinous  tubular  and  spindle  cell  carcinoma  
Xp11  translocation  carcinoma  
Clear  cell  papillary  carcinoma  said  to  be  of  end-stage  renal  dis
Chromophobe  carcinoma  
Oncocytoma  
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he  pTNM  stage  indicates  the  extension  of  the  tumour.  The
uhrman  grade  and  pTNM  stage  are  applicable  regardless  of
he  nature  of  the  tumours,  the  value  of  the  Fuhrman  grade
eing  however  rather  more  relative  for  chromophobe  car-
inomas.  For  a  given  group,  they  are  the  best  prognostic
actors  [2,3].
For  a  long  time,  surgery  and  immunotherapy  (using  inter-
eron  or  interleukin)  have  been  the  only  available  means
f  treatment  in  disseminated  forms,  despite  poor  efﬁcacy.
nderstanding  the  central  role  played  by  the  VHL  gene
n  the  genesis  of  clear  cell  carcinoma,  the  most  common
orm  of  malignant  renal  tumour,  has  revolutionised  mana-
ement  of  this  cancer,  with  the  introduction  of  targeted
nti-angiogenic  treatment.  In  addition  to  the  morphological
oints  of  recognition,  our  objective  is  to  show  how  under-
tanding  the  biological  and  molecular  mechanisms  involved
n  the  genesis  of  kidney  tumours  in  adults  may  modify  the
istological  classiﬁcation.
lear cell carcinoma (CCC)
ver  80%  of  renal  carcinomas  are  of  this  type,  which  occurs
n  the  sixth  decade  of  life,  more  frequently  in  men  [1].
The  characteristic  macroscopic  appearance  of  CCC  is  that
f  a  solid  or  partially  cystic,  sulphur  yellow  tumour  with
aemorrhagic  changes  (Fig.  1).  These  small  tumours  areomas.
Genetic  alteration
—3  (3p25—26)
t  (X;1)  (p11.2;q21)  TFE3-PRCC
t  (X;17)  (p11.2;q25)  TFE3-ASPL
t  (X;1)  (p11.2;p34)  TFE3-PSF
inv  (X)  (p11.2;q12)  TFE3-nonO
t  (X;17)  (p11.2;q23)  TFE3-Clathrin
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umours  of  the  kidney.
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enerally  rounded  and  well-circumscribed.  In  large  tumours
r  after  prolonged  development,  calciﬁcation  and  possibly
ssiﬁcation  may  be  seen.  Necrotic  changes  are  also  com-
on.
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Figure 2. Multilocular cystic renal cell carcinoma: absence of
tumour mass.
Figure 3. Histology of the same tumour: ﬁne septa covered by
tumour cells.Figure 1. Clear cell carcinoma with central myxoid changes.
When  these  tumours  protrude  from  the  convexity  of  the
kidney,  we  have  to  suspect  inﬁltration  of  the  perirenal  fat,
which  is  often  not  conﬁrmed  histologically.
Histologically,  CCC  is  composed  of  clear  or  less  frequently
eosinophilic  cells  arranged  in  acini  or  pseudoalveolar  struc-
tures  or  in  compact  masses  within  a  richly  vascularised  or
myxoid  stroma.  Sarcomatoid  differentiation  can  be  seen,  as
in  other  histological  types  of  renal  tumour  (Fuhrman  grade
4).  The  immunohistochemical  proﬁle  associating  expression
of  EMA,  vimentin  and  CD10  suggests  it  originates  from  the
cells  of  the  proximal  convoluted  tubules.  The  characteristic
vascularisation  is  explained  by  the  molecular  mechanisms
involved  in  the  development  of  the  disease  affecting  the
VHL  gene  (3p25-26)  [4].  About  70%  of  patients  with  Von
Hippel-Lindau  disease  therefore  develop  a  CCC  which  is  usu-
ally  multiple  and  bilateral  and  appears  early,  before  the  age
of  40.  In  the  case  of  sporadic  clear  cell  cancer  of  the  kidney,
allelic  loss,  point  mutations  or  methylation  of  the  VHL  gene
(3p25-26)  promoter  are  almost  constant.
Multilocular cystic renal cell carcinoma
This  new  entity  in  the  2004  classiﬁcation  represents  1—4%
of  kidney  carcinomas.  It  is  a  purely  cystic  form  of  tumour
(Figs.  2  and  3).  The  mean  age  of  discovery,  which  is  often
by  chance,  is  50  years  old,  and  again,  it  is  more  frequent  in
men.  With  CT  scan,  the  lesion  is  classiﬁed  as  grade  3  or  4
according  to  the  Bosniak  classiﬁcation  with  thin  septa,  which
may  be  calciﬁed,  but  with  no  identiﬁable  mass  [5].  Size  is
variable  and  may  reach  15  cm.  Macroscopically,  it  is  a  tumour
forming  a  single  mass  divided  into  many  cystic  cavities  ﬁlled
with  clear  serous  or  haemorrhagic  ﬂuid,  separated  by  ﬁbrous
septa.
The  septa  are  lined  with  the  same  clear  cells  as  those
seen  in  the  classic  histological  form.  In  addition,  in  the  walls
of  these  cysts  there  are  small  nests  of  analogous  clear  cells.
A  sinusoidal  type  of  vascular  proliferation  can  be  seen.
The  differential  diagnosis  is  with  cystic  carcinoma  and
cystic  nephroma  (multilocular  cyst)  of  the  adult,  a  benign
tumour  in  the  REST  group  (renal  epithelial  and  stromal
tumours)  (Fig.  4)  [6,7].
Figure 4. Thick-walled, smooth cystic nephroma with no vegeta-
tion.
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aigure 5. Typical appearance of a non-functional kidney with
any cysts and a small whitish, well-circumscribed tumour.
All  the  cases  reported  in  the  literature  had  a  good  progno-
is,  and  the  question  of  the  malignant  nature  of  this  tumour
emains  open  [8].
lear cell papillary carcinoma said to be of
nd-stage renal disease
his  histological  form  has  been  individualised  recently  (it
as  not  recognised  in  the  WHO  classiﬁcation  of  2004)  [9].
irst  described  in  end-stage  renal  disease,  50%  of  the  cases
re  seen  outside  of  this  context.  Morphologically,  the  cells
re  clear  and  with  a  low  Fuhrman  grade.  They  have  a  small
entral  nucleus  giving  a  very  homogeneous  appearance  to
roliferation  of  the  tumour  (Fig.  5).  The  immunohistochem-
cal  proﬁle  of  this  tumour  is  also  characteristic  (Table  2).
ike  the  previous  form,  it  is  usually  a  low-grade  tumour,
ith  a  good  prognosis:  no  metastatic  form  has  been  reported
lthough  multifocal  forms  have  been  described.
enal carcinoma associated with XP11.2
ranslocation with TFE3 expression
his  variant  of  renal  cell  carcinoma  has  been  identiﬁed
or  a  long  time  in  young  patients  as  ‘‘juvenile  renal  cell
arcinoma’’  [10]. It  is  primarily  a  tumour  of  children  (sec-
nd  decade)  and  young  adults  who  are  most  often  female
M/F  =  1/1.4).  It  represents  at  least  30%  of  renal  carcino-
as  in  children  [11]. A  few  cases  have  been  described  in
iddle-aged  adults  and  even  after  60  years  of  age  [12]. In
dults,  the  incidence  is  probably  underestimated,  because
n  the  absence  of  cytogenetic  studies  the  tumour  may  be
onsidered  as  a  clear  cell  carcinoma  (CCC),  which  resembles
orphologically  (Fig.  6).  It  often  presents  at  an  advanced
tage,  frequently  with  lymph  node  metastases  at  diagnosis.
The  architecture  is  often  mixed  and  confusing,  combin-ng  areas  of  clear  cell  carcinoma  with  areas  of  typically
apillary  structure.  This  renal  carcinoma  is  characterised
y  speciﬁc  cytogenetic  abnormalities,  with  the  forma-
ion  of  fusion  genes  by  balanced  translocation  consistently
c
i
o
cigure 6. Malignant tumour invading the renal parenchyma and
erirenal fat, with necrotic and haemorrhagic changes.
nvolving  the  TFE3  gene  located  on  Xp11.2  and  a  partner
ene,  usually  the  PRCC  gene  located  on  1q21,  or  the  ASPL
ene  located  on  17q25  [13,14].
The  differential  diagnosis  is  between  it  and  CCC  or  a  type
 papillary  carcinoma  (see  below).  In  young  patients,  apart
rom  in  Von  Hippel-Lindau  disease,  this  diagnosis  should  be
onsidered  and  investigated  through  a  cytogenetic  study  on
resh  material.  In  older  patients,  the  diagnosis  can  be  con-
idered  when  faced  with  a  high  grade  partially  papillary
arcinoma  of  unusual  morphology  with  large  eosinophilic
nd/or  clear  cells.
The  prognosis  is  favourable  in  paediatric  patients,  par-
icularly  when  there  is  no  lymph  node  metastasis.  The  adult
orms  seem  to  be  more  aggressive.  A  recent  study  [15]  has
hown  that  the  presence  of  metastatic  lymph  nodes  and  age
ver  25  years  were  factors  for  a  poor  prognosis.  Nephrec-
omy  is  the  treatment  of  choice  for  localised  forms,  while
nti-angiogenic  treatments  have  proved  their  efﬁcacy  in
etastatic  forms  [16].
apillary tumours: adenoma and papillary
arcinoma [17]
apillary  tumours  are  the  second  most  common  group  of
idney  tumours  (approximately  10%).  They  also  occur  more
requently  in  men  in  or  around  their  ﬁfties.  Macroscopically,
apillary  carcinomas  may  be  compact  or  more  or  less  cystic
Fig.  7).  Their  size  is  variable,  small  forms  measuring  less
han  5  mm  being  considered  benign  (papillary  adenomas).
hey  are  sometimes  multifocal,  bilateral  tumours  where
n  adenoma-carcinoma  association  is  possible.  This  group
f  tumours  is  deﬁned  by  the  presence  of  papillary  archi-
ecture  in  at  least  75%  of  the  tumour  proliferation.  This  is
omposed  of  ﬁbrovascular  axes  with  larger  or  smaller  clus-
ers  of  lipophages  (cells  loaded  with  fat).  Necrotic  changes
re  more  or  less  marked,  with  the  presence  of  cholesterol
rystals.  Cytokeratin  expression,  in  particular  of  CK7,  is  an
mportant  point  in  positive  diagnosis  (Table  2).  The  presence
f  small  basophilic  cells  and  a  large  quantity  of  lipophages
haracterises  type  I papillary  carcinomas.  In  the  type  II
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Figure 7. Tumour with a friable and haemorrhagic appearance.
Figure 8. Friable, haemorrhagic tumour destroying much of the
kidney. Development from the renal parenchyma but none from the
They  are  whitish-grey  in  appearance  or  more  rarely  brown-
ish.  Haemorrhagic  or  necrotic  changes  are  rare.
Histologically,  the  architecture  is  compact,  with  tubular
areas  continuing  into  spindle  cell  areas  which  appear  to  have
come  about  by  compression  of  the  tubes.  Mitosis  is  rare.  The
spindle  cell  areas  can  in  places  be  suggestive  of  proliferation
of  smooth  muscle  cells  [19].
The  differential  diagnosis  is  made  with  the  compact  form
of  papillary  carcinoma,  metanephric  adenomas,  sarcoma-
toid  carcinomas  or  those  classed  as  renal  carcinomas  with
no  other  indication.  The  prognosis,  according  to  data  in  the
literature  and  concurring  with  the  low-grade  histological
appearance,  seems  favourable,  except  where  there  is  sar-
comatoid  differentiation.  For  some  authors,  this  group  of
tumours  should  be  put  in  the  papillary  carcinoma  group.
Neuroblastoma-associated renal cell
carcinomas
These  very  rare  papillary  carcinomas  with  eosinophilic  cells
with  an  oncocytic  appearance  occur  a  variable  time  (often
several  years)  after  a  neuroblastoma.  Apart  from  their  clin-
ical  context,  they  do  not  have  any  particular  morphological
characteristics  and  are  only  brieﬂy  mentioned  here  [20].
Oncocytic tumour/chromophobe
carcinoma group
A  chromophobe  carcinoma  occurs  in  approximately  5-7%  of
cases.  Macroscopically,  it  is  a  rounded,  compact,  homoge-
neous,  well-circumscribed,  buff  coloured  tumour  (Fig.  9).
Necrosis  and  haemorrhagic  changes  are  exceptional  and
occur  mainly  in  large  tumours.  Metastases  have  been
described  in  about  10%  of  cases.  Aggressive  variants,  partic-
ularly  with  a  sarcomatoid  appearance,  have  been  reported
[21].
Oncocytoma  occurs  with  similar  frequency  (5—7%)  [22].
Macroscopically,  this  is  a  fairly  typical,  round,  buff-brown,
compact,  well-circumscribed  tumour  with  no  haemorrhagicrenal pelvis. Differential diagnosis from the macroscopic appear-
ance: urothelial carcinoma.
variant,  cell  polymorphism  is  more  marked;  the  cells  are
more  often  eosinophilic  with  a  pseudostratiﬁed  architecture
and  have  a  higher  Fuhrman  grade.  This  form  of  carcinoma
is  considered  to  be  more  aggressive.  It  is  usually  unifocal
(Fig.  8).
The  characteristic  cytogenetic  abnormalities  of  this
tumour  group  are  essentially  abnormalities  in  the  number
of  chromosomes  7  and  17  (Table  I).
Low-grade mucinous tubular and spindle
cell carcinoma of the kidney (loopoma)
[18]
Described  for  the  ﬁrst  time  in  1998,  this  is  a  tumour
of  middle-aged  adults  (in  their  ﬁfties),  occurring  more  in
women  (M/F  sex  ratio  =  1/3).  These  tumours  are  unusual
with  less  than  80  cases  having  been  reported  in  the  litera-
ture.  Macroscopically,  they  occur  essentially  in  the  medulla,
are  well-circumscribed,  closed  and  often  homogeneous.
Figure 9. Buff coloured, multilobed, well delimited tumour, sug-
gesting either an oncocytoma or a chromophobe carcinoma.
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change  and  inﬁltrate  the  adipose  tissue  (Fig.  12).  From  the
histological  point  of  view,  they  are  characterised  by  a  very
inﬂamed  stroma  and  atypical  eosinophilic  carcinoma  celligure 10. Reddish-brown tumour with intratumoral scar: typical
ppearance of an oncocytoma.
r  necrotic  changes.  In  30%  of  cases,  a  central  ﬁbrous  scar
s  described  (Fig.  10).  Elsewhere,  the  appearance  may  be
ystic.  An  oncocytoma  can  become  very  large.
Histologically,  an  oncocytoma  is  made  up  entirely  of  fairly
arge,  eosinophilic  cells  with  a  central  round  nucleus,  which
ore  rarely  may  be  irregular  or  atypical.  The  cytoplasm
ontains  many  mitochondria.  Conversely,  chromophobe  car-
inoma  cells  often  have  a  wrinkled  nucleus  with  an  irregular
utline,  with  a  clear  perinuclear  halo;  they  also  have  lighter
ytoplasm  and  a  clearly  visible  membrane,  outlining  the
ytoplasm.
However,  it  is  sometimes  difﬁcult  to  differentiate
etween  oncocytomas  and  chromophobe  carcinomas  both
rom  an  architectural  and  a  cytological  point  of  view.
ale’s  colloidal  iron  stain  shows  up  diffuse  intracytoplasmic
icrovesicles,  in  contrast  to  the  oncocytoma  where  there
s  focal  apical  staining.  Moreover,  expression  of  E-cadherin
nd  c-kit  seem  to  be  more  frequent  in  chromophobe  carci-
omas.
ncocytomatosis [23]
he  presence  of  many  oncocytomas  of  varying  sizes  in  both
idneys  of  the  same  patient  is  known  as  oncocytosis  or  onco-
ytomatosis.  Clinically,  this  rare  occurrence  may  be  seen  at
ny  age.  There  is  usually  one  or  more  oncocytoma,  possibly
easuring  several  centimetres,  that  leads  to  surgery.  These
esions  can  also  be  unilateral,  especially  where  a  kidney
s  atrophic  with  parenchymal  destruction.  Macroscopically,
here  are  multiple  nodules  measuring  centimetres  or  mil-
imetres,  with  small  cysts.
Histologically,  these  nodules  or  cysts  are  composed  of
ncocytic  cells  and  small  islets  of  oncocytes  are  scattered
n  the  parenchyma.
irt-Hogg-Dubé syndrome (BHD)his  is  an  autosomal  dominant  genodermatosis  with
enign  skin  tumours  (trichodiscomas,  ﬁbrofolliculomas,
crochorda)  of  the  face  and  trunk  that  can  be  associated
F
a
oigure 11. Multiple tumours of different macroscopic appear-
nce.
ith  tumours  of  the  colon  and  a  pneumothorax.  Kidney
umours  seem  to  develop  in  15  to  30%  of  patients,  but
hese  tumours  can  vary  histologically  (Fig.  11)  [24]. The
ene  responsible  for  the  disease  (folliculin:  17p11)  acts  as  a
umour  suppressor  gene.  In  practice,  if  faced  with  multiple
idney  tumours  of  the  chromophobe  carcinoma  and  oncocy-
oma  type,  with  or  without  skin  lesions,  investigation  of  the
amily  should  be  offered.
ellini duct carcinoma [25]
hese  represent  less  than  1%  of  kidney  tumours  and  occur
ost  often  in  men  in  their  ﬁfties,  sometimes  earlier,  and
lways  have  a  poor  prognosis.
Macroscopically,  they  are  usually  hilar  tumours  and
lready  at  the  extended  stage  at  the  time  of  the  initial  diag-
osis.  They  are  poorly  delimited,  show  considerable  necroticigure 12. Bellini duct carcinoma. The kidney and perirenal fat
re completely occupied by a necrotic haemorrhagic tumour; myx-
id areas on the left.
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masses,  forming  a  vaguely  tubular  or  trabecular  architec-
ture.
A  very  aggressive  variant  has  been  found  in  young  people
less  than  40  years  of  age  with  sickle  cell  trait,  known  as
renal  medullary  carcinoma.  For  unexplained  reasons,  these
tumours  are  more  frequently  on  the  right  side.  Molecular
biology  studies  discuss  a  similarity  with  urothelial  carcinoma
of  the  renal  pelvis.  Survival  is  usually  less  than  15  weeks
[26].
Angiomyolipomas
Angiomyolipomas  (AML)  are  benign  renal  tumours.  Their
place  in  this  survey  may  therefore  appear  strange.  However,
apart  from  the  fact  that  some  (epithelioid)  forms  of  AML  are
differential  diagnoses  for  renal  carcinomas,  the  molecular
mechanisms  underlying  their  formation  justify  their  inclu-
sion  in  this  topic.
AMLs  occur  in  the  kidney  either  sporadically  or  as
part  of  tuberous  sclerosis  (Bourneville’s  disease).  In
patients  between  25  and  35  years  old  with  tuberous
sclerosis,  the  incidence  of  AML  is  estimated  to  be  50%
[27].
AML  occurs  four  to  ﬁve  times  more  often  in  women  than
in  men.  When  small,  they  are  often  located  subcapsularly.
They  may  have  several  extensions  into  the  kidney,  which
may  merge  together,  or  they  can  extend  into  the  renal  fat
without  invading  it  (Fig.  13).  Some  AMLs  may  merge  going
so  far  as  to  inﬁltrate  the  whole  kidney.  A  number  of  AMLs
have  been  described  extending  into  the  lumen  of  vessels,
the  renal  vein  and  vena  cava,  without  nevertheless  altering
their  prognosis.
The  macroscopic  appearance  depends  on  the  respective
proportions  of  the  three  cell  types:  adipose,  muscle  and  vas-
cular  cells.  In  a  pararenal  site,  it  can  be  very  difﬁcult  to
diagnose  an  AML,  if  it  is  predominantly  formed  from  muscle
or  fat  tissue.  The  differential  diagnosis  is  between  it  and
a  leiomyosarcoma  or  a  liposarcoma.  Angiomyolipomas  are
benign  tumours  with  the  exception  of  a  few  reported  cases
of  epithelioid  angiomyolipoma  (an  atypical  variant  that  had
a  fatal  outcome).
Figure 13. Centrally growing angiomyolipoma.
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enal epithelioid angiomyolipoma
he  epithelioid  variant  of  angiomyolipoma  (AML)  was
escribed  by  two  teams  in  1997  and  1998  [28,29].  The
rst  cases  described  reported  a  poor  prognosis,  in  contrast
o  the  usual  good  prognosis  for  AML.  Recent  publications
ave  conﬁrmed  this  poor  prognosis,  with  the  appearance  of
ymph  node  or  visceral  metastases  in  nearly  a  third  of  cases
here  there  is  atypia,  mitosis  and  necrosis  [30]. It  is  a  renal
r  pararenal  perivascular  epithelioid  cell  tumour  (PEComa)
ith  epithelioid  morphology,  which  occurs  with  equal  fre-
uency  in  men  and  women,  particularly  in  their  forties.  More
han  half  of  the  cases  are  seen  in  the  context  of  tuberous
clerosis  (TS).
The  tumour  is  usually  large  (more  than  6  cm),  compact,
reyish  white,  poorly  deﬁned,  with  haemorrhagic  changes.
icroscopically,  tumour  proliferation  consists  of  spindle
ells  often  with  abundant  clear  cytoplasm  and  large,
osinophilic,  epithelial-like,  polygonal  or  ovoid,  globular
ells  (Fig.  14).
The  basic  differential  diagnosis  is  with  eosinophilic  renal
ell  carcinoma.  Immunolabelling  (HMB45,  Melan,  A  Mitf)  is
ssential  here.
he impact of genetic studies on
nderstanding familial forms and targeted
herapy
amilial syndromes
able  3  sets  out  the  main  familial  syndromes  in  which  renal
umour  involvement  is  seen,  with  the  genes  involved.
he genetic bases of targeted therapies
he  frequency  of  alterations  to  the  VHL  gene  or  its  prod-
ct  (mutation,  deletion,  methylation)  have  made  renal
umours  a  particular  area  for  applying  targeted,  essen-
ially  anti-angiogenic,  therapies  [31]. As  in  many  other
umoral  processes,  kidney  tumours  are  characterised  by
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Table  3  Main  genetic  syndromes  with  renal  involvement.
Syndrome  Gene  Chromosome  Renal  effect  Other  organs  involved
VHL  (Von
Hippel-Lindau)
VHL  3p25  Multiple  bilateral  renal
carcinomas  and  renal
cysts
Haemangioblastomas  of
the  cerebellum  and
retina,
pheochromocytomas,
pancreatic  cysts  and
endocrine  tumours,
tumours  of  the
endolymphatic  sac  and
inner  ear,  cystadenomas
of the  epididymis  and
the  broad  ligament
Hereditary  papillary
carcinoma
C-MET  7q31  Bilateral  and  multiple
type  1  papillary
carcinomas  of  the  kidney
Hereditary
leiomyomatosis  and
carcinomas  of  the
kidney
FH  (fumarate
hydratase)
1q42 Non  type  1  papillary
carcinomas  of  the  kidney
Uterine  leiomyomas  and
leiomyosarcomas
Birt-Hogg-Dubé BHD  (folliculin) 17p11  Oncocytomas,
chromophobe  carcinoma,
hybrid  tumours,  bilateral
and  multiple  oncocytic
papillary  carcinomas
Pulmonary  cysts,
spontaneous
pneumothorax,  facial
ﬁbrofolliculomas
Tuberous  sclerosis  (TSC
syndrome,
Bourneville’s  disease)
TSC1  9q34  Angiomyolipomas,  lym-
phangioleiomyomatosis,
bilateral  and  multiple
renal  cysts
Cardiac  rhabdomyomas,
adenomatoid  polyposis
of  the  duodenum  and
small  intestine,
pulmonary  cysts,  cortical
tuberosities  and
subependymal  giant  cell
tumours  etc.
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ocal  vascular  growth,  the  function  of  which  is  to  provide
he  tumoral  process  with  the  oxygen  needed  to  grow.  This
eoangiogenesis  is  particularly  marked  here,  as  the  histo-
ogical  appearance  of  CCCs  shows,  due  to  the  involvement
f  the  VHL  gene  the  product  of  which  plays  a  crucial  role
n  regulating  the  response  to  hypoxia.  Under  hypoxic  con-
itions,  HIF1 and  HIF1 form  a  complex  that  induces  the
ynthesis  of  VEGF  and  other  growth  factors  responsible
or  neovascularisation.  In  normoxic  conditions,  the  prod-
ct  of  the  VHL  gene  prevents  the  formation  of  an  efﬁcient
IF1  complex  and  thus  the  synthesis  of  angiogenic  fac-
ors.  In  the  case  of  renal  CCC,  loss  or  mutation  of  the
HL  tumour  suppressor  genes  results  in  the  activity  of  the
IF1  complex  being  maintained.  Local  secretion  of  growth
actors  leads  to  stimulation  of  the  PI-3-kinase  pathway  or
argets  of  the  RAS  pathway,  activating  the  synthesis  of
IF,  which  in  turn  results  in  uncontrolled  stimulation  of
ngiogenic  factors.  While  anti-VEGF  therapies  speciﬁcally
arget  the  VEGF  pathway,  being  either  directly  anti-VEGF
bevacizumab)  or  anti-tyrosine  kinase  receptors  (sunitinib,
azopanib,  sorafenib),  the  mTOR  inhibitors  (temsirolimus,
verolimus)  act  speciﬁcally  on  cell  growth  (RAF  pathway  and
I-3-kinase)  [32].
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che role of genetic studies in the indication
or targeted therapy
he  efﬁcacy  of  these  various  drugs  has  been  demonstrated
n  metastatic  forms  of  renal  tumours,  irrespective  of  their
istological  proﬁle.  CCCs,  as  well  as  translocation  carcino-
as,  papillary  carcinomas  and  mucinous  tubular  and  spindle
ell  carcinomas  are  all  sensitive  to  these  drugs  with  similar
fﬁcacy.
At  present,  however,  two  key  issues  remain  unresolved:
hich  renal  tumours  with  purely  local  development  are
ikely  to  develop  with  a  poorer  outcome  after  surgical  resec-
ion  and  which  metastatic  renal  tumours  will  respond  best
o  a speciﬁc  targeted  therapy?
rognostic criteria
he  Fuhrman  grade  and  pT  stage  are  the  best  prognostic  fac-
ors  known  apart  from  in  a  few  speciﬁc  morphological  types.
lear  cell  papillary  tumours  (said  to  be  of  end-stage  renal
isease)  and  multicystic  forms  of  renal  carcinoma  (multi-
ystic  clear  cell  carcinoma,  tubulocystic  carcinoma)  usually
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have  a  good  prognosis  (grade  1).  Similarly,  chromophobe
carcinomas,  type  1  papillary  carcinomas  and  mucinous  tubu-
lar  and  spindle  cell  carcinomas  have  a  good  prognosis.  The
Fuhrman  grade  applied  to  CCCs  and  tubulopapillary  carci-
nomas  is  still  the  best  histo-prognostic  factor  known.  The
size  of  the  tumour  and  especially  its  extension  beyond  the
limits  of  the  renal  parenchyma  (pT3  and  beyond)  are  detri-
mental  factors  reported  in  all  the  major  series  of  patients.
To  date,  no  molecular  marker  or  multifactorial  molecular
model  has  been  demonstrated  to  have  a  predictive  value
[33].
Predicting the therapeutic response
The  answer  to  this  question  is  more  complex.  The  main
prognostic  models  in  use  employ  pre-treatment  clinical
characteristics  (performance  status,  free  interval,  number
of  metastases  and  laboratory  variables  -  serum  calcium,
haemoglobin  and  lactate  dehydrogenase  concentrations).
These  models  are  still  relevant  but  are  inadequate  for
determining  the  response  to  anti-angiogenic  agents.  Certain
authors  have  studied  the  nature  of  the  alterations  in  the  VHL
gene  and  their  impact  on  responses  to  targeted  therapies
[34].
For  these  authors,  simple  inactivation  of  the  VHL  gene
(for  example,  by  methylation  of  its  promoter)  had  no  signiﬁ-
cant  impact  on  the  therapeutic  response.  On  the  other  hand,
loss  of  function  by  mutation  of  the  reading  frame  (deletion,
insertion,  nonsense  mutation)  was  associated  with  a  better
therapeutic  response.
In  parallel  to  study  of  Von  Hippel-Lindau  disease,  study
of  familial  forms  of  papillary  carcinoma  of  the  kidney
emphasised  the  role  of  MET  (7q31-34)  in  the  genesis  of
renal  carcinomas.  Activation  of  the  MET  tyrosine  kinase
domains,  after  binding  of  its  HGF  (Hepatocyte  Growth  Fac-
tor)  ligand,  leads  to  recruitment  of  intracellular  targets
(GrB2,  SRC  etc.)  and  activation  of  metabolic  pathways  (PI3K,
Ras/MAPK),  involved  particularly  in  cell  migration  and  inva-
sion  [35]. Different  MET  mutations  have  been  identiﬁed  in
the  familial  forms  and  in  sporadic  cases  of  papillary  car-
cinoma  of  the  kidney  [36]. MET  could  also  be  involved  in
the  genesis  of  some  forms  of  translocation  carcinoma  [37]
and  the  development  of  the  metastatic  potential  of  clear
cell  carcinomas  (Met/-catenin  interactions)  [38]. Three
therapeutic  strategies  are  being  investigated,  aiming  to
inhibit  interaction  of  MET  with  its  ligand,  activation  of  its
tyrosine  kinase  activity  or  recruitment  of  its  intracellu-
lar  effectors,  alone  or  in  combination  with  other  targeted
therapies  [35]. Again,  the  mutation  proﬁle  of  MET  appears
to  play  a  role  in  the  sensitivity  of  the  tumour  to  the
chemotherapy  given  [39]. Moreover,  some  serum  or  tis-
sue  markers  may  be  predictive  of  a  therapeutic  response
[40].
Other  genes  are  involved  in  familial  forms  of  kidney
cancer  (affecting  fumarate  hydratase  in  renal  carcinomas
associated  with  hereditary  leiomyomatosis  or  folliculin  in
Birt-Hogg-Dubé  syndrome)  (Table  3).  Their  precise  role  and
the  therapeutic  implications  of  changes  to  them  are  inter-
esting  ﬁelds  for  investigation  but  are  still  hypothetical
[41].
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Finally,  in  addition  to  the  involvement  of  the  mTOR
athway  in  renal  carcinogenesis,  we  must  remember  the
mportant  role  of  this  pathway  in  the  genesis  of  renal
umours  associated  with  tuberous  sclerosis  and  sporadic,
lassic  or  epithelioid  angiomyolipomas  [42,43].
onclusion
he  particular  place  of  VHL  and  the  metabolic  pathways  con-
rolling  angiogenesis  has  made  kidney  tumours  a  particularly
xciting  ﬁeld  of  investigation  for  targeted  therapies.  Fur-
hermore,  the  large  number  of  genetic  syndromes  associated
ith  renal  tumours  opens  promising  therapeutic  perspec-
ives.  However,  while  the  classiﬁcation  of  renal  tumours
as  been  enriched  by  new  entities,  some  of  which  are
ot  yet  included  in  the  latest  WHO  classiﬁcation,  distinc-
ion  between  the  various  entities  making  up  this  group  is
till  based  essentially  on  clinical  and  histological  criteria,
upported  by  the  existence  of  speciﬁc  immunohistochemi-
al  and  sometimes  cytogenetic  proﬁles.  The  all-molecular
poch  is  still  hypothetical.
TAKE-HOME  MESSAGES
General  concepts:
• tumour  classiﬁcation  contains  many  variants,
which  are  sometimes  difﬁcult  to  classify,  even
histologically.  The  key  element  is  the  morphological
appearance;
• the  two  factors  for  the  histological  prognosis  of  a
renal  cancer  are:
◦  the  Fuhrman  grade,  which  applies,  above  all,  to  clear
cell  carcinomas  and  less  so,  to  papillary  carcinomas,
◦  The  pTNM  stage;  since  2009,  invasion  of  the  adrenal
glands  by  the  cancer  is  considered  to  be  pT4.
Speciﬁc  concepts:
• in young  subjects,  we  must  consider  a  renal
carcinoma  associated  with  Xp11.2  translocation  with
TFE3  expression.  Often  these  are  large  tumours
(microcalciﬁcations  may  be  present).  In  metastatic
forms  the  treatment  of  choice  is  chemotherapy  after
surgery;
• there  are  many  cystic  lesions,  the  largest  group  being
the  REST  group,  followed  by  multilocular  cystic  renal
cell  carcinomas.  All  of  these  have  a  good  prognosis;
• many  genetic  syndromes  exist,  the  most  important
being  the  Von  Hippel-Lindau  (VHL)  syndrome.  These
syndromes  must  be  considered  where  there  are
multiple  lesions;
• genetic  studies  have  an  impact  on  predicting  the
response  to  targeted  therapies.isclosure of interest
he  authors  declare  that  they  have  no  conﬂicts  of  interest
oncerning  this  article.
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